經導管支架及經導管主動脈瓣的技術創新 是由出版商Business Insights在2011年11月所出版的。
這份英文市場調查報告書包含Pages: 70 價格從美金3835起跳。
經皮經管血管新生策略的全球市場2010年實際成果為91億美元的銷售額規模，預計2016年的年度複合成長率為13.8％達到191億美元。支撐這個市場成長的因素為美國和日本的人口高齡化，亞洲的該技術的普及擴大等手術數量的增加等因素。
本報告提供經皮冠狀動脈擴張術(PTCA)及經導管主動脈瓣(TAV)的領域的技術創新為焦點，分就其發展驗證，藥劑溶出性血管支架和藥物塗層球囊，栓塞保護裝置，經導管瓣膜等的設備，及各產品領域的法規情形相關的最新資訊蒐集，為您概述為以下內容。
摘要整理
- 經皮冠狀動脈功能策略(PCI)概要
- PCI產品的技術創新
- PCT技術的技術創新
- 經導管主動脈瓣的技術創新
關於作者
經皮冠狀動脈功能策略(PCI)概要
- 摘要
- 簡介
- 心臟疾病的免疫學
- PCI相關簡介
- PCI市場的規模與預測
PCI產品的技術創新
- 摘要
- 簡介
- 新技術
- 球囊導管
- 藥劑溶出性血管支架
- 藥物塗層球囊
- 栓塞保護裝置
- 血管通路的封閉裝置
PCT技術的技術創新
- 摘要
- 簡介
- 新技術
- 血管內超音波檢驗
- 冠狀動脈生理學評估
- 混合型冠狀動脈介入治療
- 輔助的PCT療法
經導管主動脈瓣(TAV)的技術創新
- 摘要
- 簡介
- 經導管主動脈瓣移植(TAVI)概要
- TAVI的市場機會
- TAV的新技術
- SAPIEN瓣膜
- CoreValve移植
- 其他臨床實驗設備
- 主要經導管主動脈瓣廠商
附錄
- 調查範圍
- 調查方法
- 用語·語彙
- 參考文獻·參照資料
Description
INTRODUCTION
This report covers innovations across the percutaneous transluminal coronary angioplasty and transcatheter aortic valve spaces. Innovations in both devices and techniques are reviewed. Devices covered include drug eluting stents, drug coated balloons, embolic protection devices and trascatheter valves. The report also examines the regulatory status of products under investigation.
FEATURES AND BENEFITS
- Assess the markets for percutaneous transluminal coronary angioplasty devices and transcatheter valves.
- Forecast epidemiology of key cardiology indications which impact the PTCA and transcatheter aortic valve markets.
- Evaluate innovations in percutaneous transluminal coronary angioplasty devices.
- Analyze how percutaneous transluminal coronary angioplasty techniques are changing.
- Gain an understanding of the leading transcatheter aortic valves which are under investigation for approval.
HIGHLIGHTS
The global market for percutaneous transluminal angioplasty is valued at $9.1bn in 2010, and is set to grow at a CAGR of 13.8% to reach $19.1bn in 2016. The market is being driven by the rise in procedural volumes with an increase in the average age of the population in the US and Japan, and the increase in the penetration of PCI in Asia.
Future directions in the DES space focus on inventing DES that are safer (lower risk of thrombosis), more maneuverable in order to treat dispersed lesions, and have novel therapeutic properties, such as self-expandable DES, bifurcation stents and DES with more than one drug offering.
New imaging techniques are the main area of innovation in transcatheter aortic valves. Edwards Lifesciences Sapien valve became the first product to be approved in the US.
YOUR KEY QUESTIONS ANSWERED
- How are PTCA techniques changing?
- Which companies are developing transcatheter aortic valves and what stages of development are they at?
- What factors are driving the PTCA device market?
- Where is the greatest potential for drug coated balloons?
- How are adjunct therapies for PTCA being used?
Table of Contents
Executive Summary
- Overview of percutaneous coronary intervention
- Innovations in PCI products
- Innovations in PCI techniques
- Innovations in transcatheter aortic valves
About the author
Overview of percutaneous coronary intervention
- Summary
- Introduction
- Epidemiology of cardiovascular diseases
- Introduction to PCI
- Market size and forecasts for PCI
- Historical market size and forecasts
Innovations in PCI products
- Summary
- Introduction
- Innovations
- Balloon catheters
- Drug-eluting stents
- Drug coated balloons
- Embolic protection devices
- Vascular access closure devices
Innovations in PCI techniques
- Summary
- Introduction
- Innovations
- Intravascular ultrasonography
- Coronary physiologic assessment
- Hybrid coronary intervention
- Adjunct PCI therapies
- Anti-coagulants used in PCI
Innovations in transcatheter aortic valves
- Summary
- Introduction
- Etiology of valve disease
- Introduction to TAVI
- Market opportunities in TAVs
- Innovations in TAV
- Sapien valve
- CoreValve prosthesis
- Other investigational devices
- Leading trancatheter aortic valve manufacturers
Appendix
- Scope
- Methodology
- Glossary/Abbreviations
- Bibliography/References
